- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.
Keywords: TB, HIV, drug-resistant, treatment, support and care
Most countries are not on track and too many people living with HIV are still dying from TB which is preventable and curable. The most vulnerable and the marginalized are still out of reach of HIV and TB services and in around 40 countries the number of TB deaths among people living with HIV is increasing. This is unacceptable.
In November 2017, 117 national delegations adopted the Moscow Declaration to End TB at the first WHO Global Ministerial Conference on Ending TB: A Multisectoral Response. They committed to “supporting the development of a multisectoral accountability framework” to accelerate progress to end TB. They called on WHO to develop the framework, working in close cooperation with relevant partners.
At the 71st World Health Assembly (WHA) in May 2018, Member States welcomed the WHO draft multisectoral accountability framework (hereafter referred to as the MAF-TB). The WHA also requested the Director-General to continue to develop the MAF-TB, in consultation with Member States, and working in close collaboration with partners, as well as to provide technical support for national adaptation and use of the MAF-TB.
Keywords: SDG, TB, development, funding, monitoring and reporting
This was the first year of the new funding cycle for the Multi-Country Western Pacific Integrated HIV/tuberculosis (TB) Programme. The three-year (2018-2020) US$11,368,713 programme is supported by the Global Fund and aims to strengthen control of HIV and TB in 11 Pacific island countries: Cook Islands, Federated States of Micronesia, Kiribati, Nauru, Niue, Palau, Republic of Marshall Islands, Samoa, Tonga, Tuvalu and Vanuatu. The United Nations Development Programme is the programme’s Principal Recipient.
Drug-resistant TB is part of the growing challenge of antimicrobial-resistant superbugs that do not respond to existing medications, resulting in fewer treatment options and increasing mortality rates for illnesses that would ordinarily be curable – including TB. Global development partners must move faster to contain this threat of antimicrobial resistance (AMR) before it escalates to claim millions of lives around the world.
Concerted and integrated efforts are needed to prevent and address both TB and TB-HIV burden in the region.
2 out of 3 TB infections globally are in Asia and the Pacific and 60% of MDR-TB burden is in this region. Globally, Asia and the Pacific is the home for 13% of PLHIV but 20% of TB-HIV co-infections are in this region. Systematic collaboration between TB-HIV programmes will save lives and improve the quality of life of people living with and affected by HIV and TB.
The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or symptoms of TB in seeking diagnosis, treatment and care; and includes key algorithms and cross-cutting elements that are essential to a patient-centered approach in the cascade of TB care.
The WHO South-East Asia (SEA) Region has some of the highest TB-burden countries, and nearly half of all TB cases in the world are to be found in people from this Region. The Region has nearly half the global burden in terms of new cases (incidence), and close to 40% of the burden in terms of deaths due to TB. And this while only 26% of the global population lives in the Region.
Keywords: TB, drug-resistant, treatment, funding